Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals' stockholders approved an amendment to the Certificate of Incorporation to increase the number of authorized shares of common stock from 300 million to 450 million shares. This decision was made at the Annual Meeting, where stockholders also elected three Class III Directors and ratified Deloitte & Touche LLP as the independent registered public accounting firm for the year ending December 31, 2026.

Eledon Pharmaceuticals announced new long-term data from its Phase 2 BESTOW clinical program for tegoprubart in kidney transplantation, presented at the American Transplant Congress. The data showed tegoprubart-treated patients maintained significantly higher mean eGFR at 18 months and experienced no biopsy-proven acute rejection events after the first six months post-transplant, unlike the tacrolimus arm. Patient-reported outcomes also favored tegoprubart, demonstrating improved symptom burden. Following a successful FDA End-of-Phase 2 meeting, Eledon plans to advance tegoprubart into Phase 3 clinical development in late 2026.

Eledon Pharmaceuticals announced updated positive results from an investigator-initiated trial evaluating tegoprubart in type 1 diabetes patients undergoing allogeneic islet cell transplantation. All 12 patients (100%) achieved insulin independence, no longer requiring exogenous insulin therapy, and demonstrated an HbA1c below 6.5%, with a mean of approximately 5.4%. This represents an average 2.6% improvement from baseline, with no severe hypoglycemic episodes reported post-transplant. The tegoprubart-based immunosuppression regimen was well tolerated, avoiding toxicities associated with calcineurin inhibitors, and the company plans to seek regulatory guidance from the FDA later this year.

Eledon Pharmaceuticals announced that updated results from an investigator-initiated trial will be presented at the American Diabetes Association 86th Scientific Sessions. The presentation, titled "Anti-CD40L to Induce Graft Survival and Function in Islet Allotransplantation," will be delivered by Dr. Piotr Witkowski from the University of Chicago Medicine Transplant Institute on June 7, 2026. This highlights the ongoing development of Eledon's lead product, tegoprubart, an anti-CD40L antibody, for various immune-modulating therapies.

Eledon Pharmaceuticals announced it will present new clinical data from its tegoprubart program at the American Transplant Congress (ATC) from June 20-24, 2026. The presentations will include updated results from the Phase 2 BESTOW clinical trial and new long-term data from the Phase 2 BESTOW extension study. The company will also host a conference call on June 22, 2026, to discuss the updated data.

Eledon Pharmaceuticals reported a significant widening of its net loss to $39.0 million for the first quarter of 2026, compared to a $6.5 million loss in Q1 2025. This was largely driven by an $18.9 million negative change in the fair value of warrant liabilities. Research and development expenses also increased to $17.2 million. As of March 31, 2026, the company's cash and cash equivalents decreased to $6.2 million, and total current assets fell to $113.6 million. Eledon anticipates its existing funds will cover operations for at least the next 12 months but expects to require additional financing.

Eledon Pharmaceuticals reported its first quarter 2026 financial results and significant business highlights. The company announced that its investigational product, tegoprubart, achieved 100% insulin independence in 10 patients with type 1 diabetes following islet transplantation in an investigator-led study. Additionally, tegoprubart received FDA Orphan Drug designation for liver transplantation and showed positive 24-month data in kidney transplantation. Financially, Eledon reported a net loss of $39.0 million for Q1 2026, an increase from $6.5 million in Q1 2025, largely due to non-cash warrant liabilities, and holds $111.1 million in cash, expected to fund operations into Q2 2027.

Eledon Pharmaceuticals reported its Q1 2026 operating and financial results, highlighting significant progress in its tegoprubart program. Key achievements include 100% insulin independence in 10 type 1 diabetes patients following islet transplantation in an investigator-led study, and FDA Orphan Drug designation for tegoprubart in liver transplantation. The company ended the quarter with $111.1 million in cash, cash equivalents, and short-term investments, expecting to fund operations into Q2 2027, despite a net loss of $39.0 million.

Eledon Pharmaceuticals, Inc. announced its 2026 Annual Meeting of Stockholders will take place on June 18, 2026. Stockholders will vote on the election of three Class III directors, an amendment to increase authorized common stock from 300,000,000 to 450,000,000 shares, and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the year ending December 31, 2026. The record date for voting is April 20, 2026, with 77,187,823 shares outstanding.